Citations

Showing 10 of 108162 citations.

Quantification of lung surface wave speed in a water-filled lung: An ex vivo swine lung study
Zhang, Alex X. , Zhang, Xiaoming , Zhou, Boran

Mayo Clinic

The Journal of the Acoustical Society of America | November 14, 2019 | Volume: 146 | Issue: 4_Supplement | Pages: 3070-3070

10.1121/1.5137653 Get It

Lung edema is a common symptom of congestive heart failure and inflammatory conditions, such as acute respiratory distress syndrome. Currently, computed tomography (CT) is considered the standard to assess lung edema, but it requires ionizing radiation and poses a significant logistic burden. Lung ultrasound (LUS) has previously been used to assess lung edema using ultrasound B-line artifacts, but analysis of the B-line artifacts relies on visual interpretation. We developed lung ultrasound surface wave elastography (LUSWE) to measure lung surface wave speed safely. This project aims to evaluate LUSWE to quantify lung surface wave speed in an ex vivo water-filled swine lung. The lung surface wave speeds were measured at baseline and at frequencies of 100 Hz, 200 Hz, 300 Hz, and 400 Hz. Then, an amount of water was filled into the lung through its trachea. Ultrasound imaging was used to guide the water filling until significant changes were visible on the imaging. The lung surface wave speeds were measured. An additional 120 ml of water was then filled into the lung. The lung surface wave speeds were measured again. The results demonstrated that the lung surface wave speed decreased with respect to water content.
Using multiparametric ultrasound-based elastographic characterization for evaluation of renal transplants
Vasconcelos, Luiz , Vasconcelos, Luiz , Urban, Matthew W. , Kijanka, Piotr

Mayo Clinic

The Journal of the Acoustical Society of America | November 14, 2019 | Volume: 146 | Issue: 4_Supplement | Pages: 2863-2863

10.1121/1.5136933 Get It

Renal transplant is a long-term therapy for patients in end-stage renal disease. Renal transplant health is monitored using laboratory tests and renal biopsy. However, renal biopsy is invasive and has issues with sampling errors. Ultrasound-based shear wave elastography (SWE) is being evaluated in renal transplants to identify patients with early stages of interstitial fibrosis and inflammation. We are exploring the use of new image reconstruction approaches such as local phase velocity imaging (LPVI) to evaluate viscoelasticity in a cohort of 23 renal transplants. Additionally, from point SWE measurements we have compiled results from 97 patients and have used various machine learning approaches to differentiate patients without disease such as interstitial fibrosis, inflammation, or interstitial fibrosis with tubular atrophy (IFTA). The LPVI method provides two-dimensional maps of phase velocity and images of viscoelastic parameters after fitting to a rheological model. The machine learning approaches combine multiple elastographic parameters to provide differentiation with high sensitivity, specificity, and accuracy (∼ 85%–90%). These approaches could have substantial benefit for patients for identifying early disease in renal transplants that my precede changes in laboratory test results.
Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women
Prague, Julia , Abbara, Ali , Comninos, Alexander , Jayasena, Channa , Higham, Claire , Adaway, Jo , Keevil, Brian , Veldhuis, Johannes D. , Dhillo, Waljit S. , Jayasena, Channa N

Mayo Clinic

Journal of the Endocrine Society | November 14, 2019 | Volume: 4 | Issue: 2 | Pages: No page available

10.1210/jendso/bvz009 | PMID 32318647 Get It

Abstract Background Neurokinin 3 receptor (NK3R) antagonism is a promising novel treatment for menopausal flashes. However, to avoid adverse hormonal effects it is clinically important to first confirm whether gonadotropin and estradiol concentrations change as a result of their administration. Methods Single-center, randomized, double-blind, placebo-controlled, crossover trial of an oral NK3R antagonist (MLE4901) in 28 women aged 40 to 62 years, experiencing >7 hot flashes/24 h; some bothersome or severe (Clinicaltrials.gov, NCT02668185). Weekly serum gonadotropins and estradiol levels were measured using commercially available automated immunoassays a priori. Serum estradiol was also measured post hoc using a highly sensitive direct assay by liquid chromatography tandem mass spectrometry. Hormone levels were compared by the paired sample t tests or by the Wilcoxon matched-pairs signed rank test, as appropriate for the distribution of the data. Results Mean (standard deviation) serum follicle-stimulating hormone (FSH) concentration was not significantly increased when taking MLE4901 (72.07 ± 19.81 IU/L) compared to placebo (70.03 ± 19.56 IU/L), P = .26. Serum estradiol was also not significantly altered, irrespective of which assay method was used (median interquartile range of serum estradiol by immunoassay: placebo 36 ± 3 pmol/L, MLE4901 36 ± 1 pmol/L, P = .21; median serum highly sensitive estradiol: placebo 12 ± 16 pmol/L, MLE4901 13 ± 15 pmol/L, P = .70). However, mean (standard deviation) serum luteinizing hormone concentration significantly decreased with MLE4901 (27.63 ± 9.76 IU/L) compared to placebo (30.26 ± 9.75 IU/L), P = .0024. Implication NK3R antagonists do not increase serum estradiol or FSH despite their reduction in hot flashes. This is clinically significant and highly reassuring for women who have a contraindication to conventional hormone therapy such as prior/existing breast cancer and/or thromboembolism.
Gestational diabetes prevention and treatment: a protocol for developing core outcome sets
Egan, Aoife M. , Dunne, Fidelma , Biesty, Linda , Bogdanet, Delia , Dempsey, Eugene , Thangaratinam, Shakila , Devane, Declan , Fhelelboom, Narjes, Egan, A M , Bogdanet, D , Dunne, Fidelma P , Crowther, Caroline Anne

Mayo Clinic

BMJ Open | November 14, 2019 | Volume: 9 | Issue: 11 | Pages: e030574

10.1136/bmjopen-2019-030574 | PMID 31727651 Get It

Introduction Selective reporting bias, inconsistency in the chosen outcomes between trials and irrelevance of the chosen outcomes for women, limit the efficiency and value of research for prevention and treatment of gestational diabetes mellitus (GDM). One way to address these challenges is to develop core outcome sets (COSs). Methods and analysis The aim of this manuscript is to present a protocol for a study to develop COSs for GDM prevention and treatment. This is a three-phase project consisting of (1) a systematic review of the literature to create two lists of outcomes that have been reported in trials and systematic reviews of trials of interventions for the prevention and treatment of GDM, (2) a three-round, web-based e-Delphi survey with key stakeholders to prioritise these outcomes and (3) a consensus meeting to resolve any remaining disagreements and to agree on two COSs. Ethics and dissemination Ethical approval to conduct this study was obtained from the ethics committee at Galway University Hospitals on 13 December 2018 (Reference: C.A.2078). We will disseminate our research findings through peer-reviewed, open access publications and present at international conferences to reach a wide range of knowledge users.
Biathlon Injury and Illness Surveillance project (BIIS): development of biathlon-specific surveillance forms in English, Russian, French and German
Dyk, Carlee Van , Perera, Nirmala Kanthi Panagodage , Carrabre, James E, Manfredini, Fabio , Fitzpatrick, Jane , Van Dyk, Carlee , Panagodage Perera, Nirmala

Mayo Clinic

BMJ Open Sport & Exercise Medicine | November 14, 2019 | Volume: 5 | Issue: 1 | Pages: e000588

10.1136/bmjsem-2019-000588 | PMID 32206339 Get It

Objective The aim of this project was to adapt the English, French, German and Russian versions of the International Olympic Committee (IOC) injury and illness surveillance form to be sport-specific for use in biathlon. Methods 23 medical representatives from 16 of the 55 biathlon federations participated in this project to adapt the form and create disease coding relevant to biathlon. The English version of the IOC injury and illness surveillance form was used as the primary template. Four review rounds were used to develop electronic fillable PDF forms. The changes were then forward translated onto the Russian, French and German forms. Results Changes were made to event type to biathlon-specific events. A weekly reporting format was adopted in line with the race week format of World Cup events. Wherever possible, coding replaced free-text format to avoid translation issues. New codes were created to describe the time of injury/illness. A new symptom code was added to reflect the prevalence of respiratory infection: sore throat/cold symptoms. As the number of athletes in a team differs between weeks in the season, an additional question was added to ask for the ‘number of athletes in the team for the week’ and for the season. Conclusion This project provides a biathlon-specific injury and illness surveillance form in English, French, German and Russian. This forms the basis for surveillance that will contribute to a greater understanding of the illness and injury rate in elite biathletes and ultimately to enhanced athlete well-being and success in biathlon, and winter sports more generally.
Continuous Posterior Lumbar Plexus Nerve Block Versus Periarticular Injection with Ropivacaine or Liposomal Bupivacaine for Total Hip Arthroplasty
Johnson, Rebecca L. , Amundson, Adam W. , Sviggum, Hans P. , Mabry, Tad M. , Mantilla, Carlos B. , Schroeder, Darrell R. , Pagnano, Mark W. , Kopp, Sandra L. , Mantilla, Carlos B , Kopp, Sandra , Johnson, Rebecca L , Schroeder, Darrell , Abdel, Matthew P.

Mayo Clinic

Journal of Bone and Joint Surgery | November 14, 2019 | Volume: 99 | Issue: 21 | Pages: 1836-1845

10.2106/jbjs.16.01305 | PMID 29088038 Get It

Background: Debate surrounds the issue of whether peripheral nerve blockade or periarticular infiltration (PAI) should be employed within a contemporary, comprehensive multimodal analgesia pathway for total hip arthroplasty. We hypothesized that patients treated with a continuous posterior lumbar plexus block (PNB) would report less pain and consume less opioid medication than those treated with PAI. Methods: This investigator-initiated, independently funded, 3-arm randomized clinical trial (RCT) performed at a single high-volume institution compared postoperative analgesia interventions for elective, unilateral primary total hip arthroplasty: (1) PNB; (2) PAI with ropivacaine, ketorolac, and epinephrine (PAI-R); and (3) PAI with liposomal bupivacaine, ketorolac, and epinephrine (PAI-L) using computerized randomization. The primary outcome was maximum pain during the morning (06:00 to 12:00) of the first postoperative day (POD) on an ascending numeric rating scale (NRS) from 0 to 10. Pairwise treatment comparisons were performed using the rank-sum test, with a p value of <0.017 indicating significance (Bonferroni adjusted). A sample size of 150 provided 80% power to detect a difference of 2.0 NRS units. Results: We included 159 patients (51, 54, and 54 patients in the PNB, PAI-R, and PAI-L groups, respectively). No significant differences were found with respect to the primary end point on the morning of the first POD (median, 3.0, 4.0, and 3.0, respectively; p > 0.033 for all). Opioid consumption was low and did not differ across groups at any intervals. Median maximum pain on POD 1 was 5.0, 5.5, and 4.0, respectively, and was lower for the PAI-L group than for the PAI-R group (p = 0.006). On POD 2, maximum pain (median, 3.5, 5.0, and 3.5, respectively) was lower for the PNB group (p = 0.014) and PAI-L group (p = 0.016) compared with the PAI-R group. The PAI-L group was not significantly different from the PNB group with respect to any outcomes: postoperative opioid use including rescue intravenous opioid medication, length of stay, and hospital adverse events, and 3-month follow-up data including any complication. Conclusions: In this RCT, we found a modest improvement with respect to analgesia in patients receiving PNB compared with those receiving PAI-R, but not compared with those who had PAI-L. Secondary analyses suggested that PNB or PAI-L provides superior postoperative analgesia compared with PAI-R. For primary total hip arthroplasty, a multimodal analgesic regimen including PNB or PAI-L provides opioid-limiting analgesia. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
The Rate of Acute Kidney Injury After Total Hip Arthroplasty Is Low but Increases Significantly in Patients with Specific Comorbidities
Gharaibeh, Kamel A. , Hamadah, Abdurrahman , Kremers, Walter K. , Zoghby, Ziad , El-Zoghby, Ziad , Kremers, Walter K , Sierra, Rafael J. , Leung, Nelson

Mayo Clinic

Journal of Bone and Joint Surgery | November 14, 2019 | Volume: 99 | Issue: 21 | Pages: 1819-1826

10.2106/jbjs.16.01027 | PMID 29088036 Get It

Background: The purpose of this study was to investigate the rate and risk factors associated with the development of acute kidney injury after total hip arthroplasty, including the perioperative use of nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: We retrospectively collected the demographic and comorbidity data of all patients who underwent total hip arthroplasty between 2004 and 2014 at our institution (n = 8,949). We conducted analyses of the entire cohort and a nested case-control subset. Subjects who developed acute kidney injury were matched by age, sex, and year of surgical procedure to subjects without acute kidney injury. Variables associated with acute kidney injury were determined using univariate and multivariate logistic regressions. Results: The mean patient age (and standard deviation) was 64.6 ± 13.8 years, 48.6% of patients were male, and 114 cases (1.1%) developed acute kidney injury, mostly stage 1 (79%). Variables associated with acute kidney injury included older age (odds ratio [OR], 1.4 per decade; p < 0.001), male sex (OR, 1.78; p = 0.005), chronic kidney disease (OR, 4.6; p < 0.001), heart failure (OR, 4.5; p < 0.001), diabetes (OR, 2.1; p < 0.001), and hypertension (OR, 2.1; p = 0.007). The results were consistent in the case-control analysis. NSAIDs were not associated with acute kidney injury (OR, 1.26; p = 0.36), but were avoided in subjects at risk, making any interpretation difficult because of confounding. A risk model for acute kidney injury after total hip arthroplasty was developed for clinical use and had good discrimination (area under the curve, 0.82; p < 0.001). Conclusions: The rate of acute kidney injury after total hip arthroplasty is low, but increases significantly, from <1% to >20%, in those with several independent risk factors present preoperatively. Increasing awareness of these risk factors may help to decrease the risk of acute kidney injury after total hip arthroplasty. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Low Anterior Resection Syndrome
McKenna, Nicholas P. , McKenna, Nicholas P

Mayo Clinic

Diseases of the Colon & Rectum | November 14, 2019 | Volume: 62 | Issue: 12 | Pages: 1420-1422

10.1097/dcr.0000000000001532 | PMID 31725578 Get It

Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia
Viard, Mathias , Zhou, Weiyin , Li, Shengchao, Wang, Tao , Vogt, Aurélie , Hicks, Belynda , Burdett, Laurie, Chung, Charles C., Andrade, Kelvin de, Berndt, Sonja I. , Rothman, Nathaniel , Lan, Qing , Haagenson, Michael , Wang, Youjin , Mary, Carrington, Gadalla, Shahinaz M. , Gadalla, Shahinaz M , Savage, Sharon A. , Yeager, Meredith , Ó’hUigín, Colm , Dean, Michael , Freedman, Neal D. , Rothman, Nathaniel , Cerhan, James R. , Slager, Susan L. , Zhang, Yawei , Teras, Lauren R. , Chanock, Stephen Jacob , Spellman, Stephen R. , Willis, Amanda, Askar, Medhat , Lee, Stephanie J.

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 1224-1224

10.1182/blood-2019-128235 Get It

Introduction. Acquired severe aplastic anemia (SAA) is a life-threatening disorder characterized by severe progressive pancytopenia and hypocellular bone marrow. The etiology of acquired SAA is not understood but believed to be related to abnormal immune responses to environmental exposures. We conducted a genome-wide association study (GWAS) to identify common germline variants associated with SAA. Methods. We identified 895 patients with SAA who underwent related or unrelated hematopoietic cell transplant (HCT) with clinical data and pre-HCT blood samples available in the Center for International Blood and Marrow Transplant Research (CIBMTR) database and biorepository. Pre-HCT DNA was extracted from blood of patients with SAA and genome-wide genotyping was conducted using the Illumina OmniExpress array. We excluded 93 inherited bone marrow failure cases. The SAA cases were grouped cases into discovery and validation sets based on time of batch sample receipt. Analyses were limited to patients of European ancestry based on principal component analyses to minimize the potential effect of population stratification. Controls were genomically matched and selected from previously scanned cancer-free subjects at the Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, NCI. The final analysis included 534 acquired SAA cases (359 in the discovery set and 175 in the validation set), and 2,455 controls (1,396 in the discovery set, and 1,059 in the validation set). Results. Patients with SAA in this study received HCT between 1989-2015 at a median age of 21 years, 56% were male, and the median time between SAA diagnosis and HCT was 11 months. Strong genome-wide association signals were identified across the human leukocyte antigen (HLA) genes encoded at the major histocompatibility complex (MHC) on chromosome 6p21 (Figure 1). The top SNP was located in the P4 binding pocket of the HLA class II gene HLA-DPB1(rs1042151A>G, p.Met105Val, pooled-odds ratio [OR]=1.75, 95% confidence interval [CI]=1.50-2.03, p=1.94x10-13). The expression of HLA-DP in CD19+ cells from 175 healthy donors was significantly different by rs1042151 A>G genotype (p=2.04x10-6) (Figure 2). A second SNP near HLA-B, rs28367832G>A, also reached genome-wide significance (pooled-OR=1.49, 95% CI=1.22-1.78, p=7.27x10-9). Copy-number variant analysis and next generation sequencing also identified somatic, clonal copy-neutral loss-of-heterozygosity affecting class I HLA genes in 8.6% of the SAA cases and none of the controls. Conclusion. This SAA GWAS identified strong association signals between common germline genetic variants in HLA class I and II genes and SAA. The main SNP is associated with changes in HLA-DP expression suggesting a key role for this locus in SAA etiology. This study adds further evidence to the connection between SAA and immune dysregulation. Disclosures Cerhan: Janssen: Membership on an entity's Board of Directors or advisory committees; NanoString: Research Funding; Celgene: Research Funding. Lee:Incyte: Research Funding; Syndax: Research Funding; Amgen: Research Funding; Novartis: Research Funding; Takeda: Research Funding; Kadmon: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; AstraZeneca: Research Funding.
Durability of Hearing Preservation Following Microsurgical Resection of Vestibular Schwannoma
Dowling, Eric M. , Patel, Neil , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Link, Michael J. , Carlson, Matthew L. , Dowling, Eric M., Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | November 14, 2019 | Volume: 40 | Issue: 10 | Pages: 1363-1372

10.1097/mao.0000000000002378 | PMID 31725593 Get It

Objective:To ascertain long-term hearing outcomes in patients with serviceable hearing following microsurgical resection of sporadic vestibular schwannoma (VS).Study Design:Retrospective cohort.Setting:Tertiary academic referral center.Patients:Forty-three adult subjects with unilateral sporadic VS who had serviceable hearing (American Academy of Otolaryngology–Head and Neck Surgery [AAO-HNS] class A or B) on initial postoperative audiogram following microsurgical resection between 2003 and 2016 with a minimum of two postoperative audiograms available for review.Intervention:Surgical treatment with a retrosigmoid or middle cranial fossa approach.Main Outcome Measure:Rate of maintaining serviceable hearing, as estimated using the Kaplan–Meier method, in accordance with the 1995 and 2012 AAO-HNS guidelines on reporting hearing outcomes.Results:The median immediate postoperative pure-tone average (PTA) and word recognition score (WRS) were 31 dB and 95%, respectively. At last follow-up, the median PTA was 38 dB with a median change of 5 dB from initial postoperative audiogram, and the median WRS was 90% with a median change of 0% from initial postoperative audiogram. Eight patients developed non-serviceable hearing at a median of 4.1 years following microsurgical resection (interquartile range, 2.9–7.0). The median duration of hearing follow-up for the 35 patients who maintained serviceable hearing was 3.1 years (interquartile range, 2.2–7.5). Tumor control was achieved in 41 (95%) patients. The rate of maintaining serviceable hearing at 5 years was 81%.Conclusion:Microsurgical resection provides excellent tumor control and durable long-term hearing in those with AAO-HNS class A or B hearing postoperatively. The paradigm of proactive microsurgical resection—when the tumor is small and hearing is good—hinges on the surgeon's ability to preserve residual hearing in a very high percentage of cases at or near preoperative hearing levels to maintain an advantage over conservative observation with regard to long-term hearing preservation.